Tandem Diabetes (TNDM) Tops Q1 EPS by 14c ; Offers Guidance

Tandem Diabetes (NASDAQ: TNDM) reported Q1 EPS of ($0.30), $0.14 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $247.22 million versus the consensus estimate of $242.08 million.

GUIDANCE:

Tandem Diabetes sees FY2026 revenue of $1.06-1.08 billion, versus the consensus of $1.07 billion.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Meta pauses an AI training program that tracks employees' keystrokes after a companywide leak - Insider